Methylnaltrexone, a new peripheral mu-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects.

Abstract

Progenics Pharmaceuticals Inc and Wyeth Pharmaceuticals are developing methylnaltrexone, a micro-receptor opioid antagonist derived from naltrexone by the addition of a methyl group. The intravenous formulation of methylnaltrexone is currently in phase III clinical trials for the potential treatment of postoperative ileus.

• Authors: Florian M Reichle, Peter F Conzen
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 1 Pg. 90-100 (Jan 2008) ISSN: 1472-4472 [Print] England
• PMID: 18183536 (Publication Type: Journal Article, Review)

Chemical References

• Analgesics, Opioid
• Quaternary Ammonium Compounds
• Receptors, Opioid, mu
• methylnaltrexone
• Naltrexone

Topics

• Analgesics, Opioid (adverse effects)
• Gastrointestinal Motility (drug effects)
• Humans
• Ileus (drug therapy)
• Naltrexone (adverse effects, analogs & derivatives, pharmacology, therapeutic use)
• Postoperative Complications (drug therapy)
• Postoperative Nausea and Vomiting (chemically induced, prevention & control, therapy)
• Quaternary Ammonium Compounds (adverse effects, pharmacology, therapeutic use)
• Receptors, Opioid, mu (antagonists & inhibitors, physiology)
• Urinary Retention (chemically induced, prevention & control, therapy)